Publicaciones de resultados de Ensayos Clínicos Multicéntricos, internacionales en los que participamos como centro de referencia:
Centro de Investigación: Instituto de Neurociencias de Rosario I.N.R.
Equipo de investigadores:
Investigador principal: Dra Geraldine Luetic
Sub-investigadores: Dra. Maria Laura Menichini, Prof. Dr. Reynaldo Menichini.
- Leist TP, Comi G, Cree BA, et al. “Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial”. Lancet Neurol. 2014;13(3):257‐
- Papais Alvarenga R, Cohen JA, Monteiro Naylor R, Correale J, Luetic G, Frider N, Ritter S, Tomic D, Kappos L. “Comparison of oral fingolimod with interferon beta-1a in treatment of relapsing-remitting multiple sclerosis: Subgroup analysis of the Latin American cohort in TRANSFORMS study”. Mult Scler 2012 18: 1821-1879.
- Cohen JA, Khatri B, Barkhof F, Comi G,Hartung HP, Montalban X et al on behalf of the TRANSFORMS (TRial Assessing injectable interferoN vS. FTY720 Oral in RRMS) Study Group. “Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study”. J Neurol Neurosurg Psychiatry 2016;87:468–475.
- Khatri B, Barkhof F, Comi G, Hartung H, Kappos L, Montalban X et al. “Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study”. Lancet Neurol. 2011 Jun;10(6):520-9. Epub 2011 May 13.
- Comi G, Cohen J, Arnold D, Wynn D, Filippi M. “Phase III dose-comparison study of glatiramer acetate for multiple sclerosis”. Ann Neurol. 2011 Jan;69(1):75-82.
- Cohen JA, Barkhof F, Comi G, et al. “Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis”. N Engl J Med 2010;362:402-15.
- Pioro EP, Brooks BR, Cummings J, Schiffer R, Thisted RA, Wynn D, Hepner A, Kaye R. Safety, Tolerability, and Efficacy Results Trial of AVP-923 in PBA Investigators. “Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect”. Ann Neurol. 2010 Nov;68(5):693-702.
- Giovannoni G, Barbarash O, Casset-Semanaz F, King J, Metz L, Pardo G, Simsarian J, Sørensen P et al. “Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results”. Mult Scler, 2009 Feb; 15(2):219-228.
- O’Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung H et al. “250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study”. Lancet Neurol. (2009)8(10) 889-97. Epub 2009 Sep 2.
- Mikol D, Barkhof F, Chang P, Coyle P, Jeffery D et al. “Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomized, parallel, open-label trial”. Lancet Neurol. 2008 Oct; 7(10):903-14. Epub 2008 Sep 11.